Headlines about Cidara Therapeutics (NASDAQ:CDTX) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cidara Therapeutics earned a news impact score of 0.05 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.8962143879628 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of CDTX traded up $0.40 during trading hours on Friday, hitting $5.75. 118,840 shares of the company were exchanged, compared to its average volume of 192,257. The company has a market cap of $123.00 million, a PE ratio of -1.81 and a beta of 2.19. Cidara Therapeutics has a 52 week low of $3.70 and a 52 week high of $8.80. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.99 and a current ratio of 5.99.
Cidara Therapeutics (NASDAQ:CDTX) last released its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.10). research analysts predict that Cidara Therapeutics will post -2.61 earnings per share for the current year.
A number of research analysts have commented on the company. ValuEngine downgraded Cidara Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, June 7th. Zacks Investment Research upgraded Cidara Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 28th. WBB Securities upgraded Cidara Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, May 23rd. Finally, Cantor Fitzgerald set a $15.00 price target on Cidara Therapeutics and gave the stock a “buy” rating in a research note on Thursday, May 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $12.92.
In related news, CEO Jeffrey Stein purchased 212,766 shares of the firm’s stock in a transaction dated Wednesday, May 23rd. The stock was bought at an average price of $4.70 per share, for a total transaction of $1,000,000.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 15.20% of the company’s stock.
About Cidara Therapeutics
Cidara Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates.
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.